PMID- 38313181
OWN - NLM
STAT- MEDLINE
DCOM- 20240206
LR  - 20240206
IS  - 1844-3117 (Electronic)
IS  - 1844-122X (Print)
IS  - 1844-122X (Linking)
VI  - 16
IP  - 10
DP  - 2023 Oct
TI  - Assessing pyridoxine adjuvant therapy effects on blood glucose levels in type 2 
      diabetes: A randomized clinical trial.
PG  - 1474-1481
LID - 10.25122/jml-2023-0178 [doi]
AB  - Pyridoxal-5-phosphate (PLP) is the bioactive derivative of vitamin B6, 
      functioning as a coenzyme in over 150 metabolic pathways. Insufficient PLP levels 
      could be associated with the onset and progression of diabetes. This study aimed 
      to assess the effects of pyridoxine adjuvant treatment on blood glucose levels in 
      patients with type 2 diabetes mellitus (T2DM). This interventional, randomized, 
      open-label study was conducted in the Mesan Governorate, with participants from 
      the Mesan Center for Diabetes and Endocrinology as the study population. This 
      study included patients newly diagnosed with T2DM. Patients were randomized into 
      three groups: Group 1, the control group, treated with non-pharmacological 
      therapy (lifestyle modification) (n=20); Group 2, treated with Metformin 500 
      mg/day in addition to non-pharmacological therapy (lifestyle modification) 
      (n=20). Group 3 was treated with Metformin 500 mg/day plus vitamin B6 300 mg/day 
      in addition to non-pharmacological therapy (lifestyle modification) (n=68). The 
      findings revealed a considerably favorable impact of pyridoxine adjuvant 
      treatment with Metformin on blood glucose levels and other study variables. 
      Compared to the patients in the control group G1, the reductions in fasting 
      plasma glucose (FPG) and glycated hemoglobin (HbA1c) were statistically 
      significant in groups G2 and G3 after a 4-week treatment period. Similar results 
      were observed for fasting serum insulin and homeostasis model assessment of 
      insulin resistance (HOMA-IR) levels, with a significant decrease in groups G2 and 
      G3 (p<0.05). Furthermore, the reductions in indoleamine 2,3-dioxygenase levels 
      were also significantly higher in groups G2 and G3 at the end of the 4-week 
      treatment period (-14.48% vs -21.16%) (p<0.05). Adding pyridoxine adjuvant 
      therapy to Metformin treatment could effectively improve the blood glucose levels 
      of patients with T2DM.
CI  - (c) 2023 The Author(s).
FAU - Dawood, Moatamad Hanoon
AU  - Dawood MH
AD  - Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, 
      Baghdad, Iraq.
FAU - Abdulridha, Manal Khalid
AU  - Abdulridha MK
AD  - Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, 
      Baghdad, Iraq.
FAU - Qasim, Hayder Saadoon
AU  - Qasim HS
AD  - Department of Medicine, College of Medicine, Maysan University, Maysan, Iraq.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Romania
TA  - J Med Life
JT  - Journal of medicine and life
JID - 101477617
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Blood Glucose)
RN  - KV2JZ1BI6Z (Pyridoxine)
RN  - 9100L32L2N (Metformin)
RN  - 0 (Insulin)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Hypoglycemic Agents/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Pyridoxine/therapeutic use
MH  - *Metformin/therapeutic use
MH  - Insulin/therapeutic use
PMC - PMC10835547
OTO - NOTNLM
OT  - glycemic control
OT  - metformin
OT  - pyridoxine adjuvant therapy
OT  - type 2 diabetes
OT  - vitamin
COIS- The authors declare no conflict of interest.
EDAT- 2024/02/05 06:43
MHDA- 2024/02/06 06:42
PMCR- 2023/10/01
CRDT- 2024/02/05 04:33
PHST- 2023/06/10 00:00 [received]
PHST- 2023/08/09 00:00 [accepted]
PHST- 2024/02/06 06:42 [medline]
PHST- 2024/02/05 06:43 [pubmed]
PHST- 2024/02/05 04:33 [entrez]
PHST- 2023/10/01 00:00 [pmc-release]
AID - JMedLife-16-1474 [pii]
AID - 10.25122/jml-2023-0178 [doi]
PST - ppublish
SO  - J Med Life. 2023 Oct;16(10):1474-1481. doi: 10.25122/jml-2023-0178.